CANTA Stock Overview
Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Cantargia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr3.42 |
| 52 Week High | kr6.08 |
| 52 Week Low | kr2.56 |
| Beta | 1.57 |
| 1 Month Change | -17.64% |
| 3 Month Change | -1.78% |
| 1 Year Change | -38.80% |
| 3 Year Change | -89.27% |
| 5 Year Change | -81.01% |
| Change since IPO | -62.02% |
Recent News & Updates
Recent updates
We're A Little Worried About Cantargia's (STO:CANTA) Cash Burn Rate
Apr 25
Is Cantargia (STO:CANTA) In A Good Position To Deliver On Growth Plans?
Jun 28We Think Cantargia (STO:CANTA) Can Afford To Drive Business Growth
Mar 08Is Cantargia (STO:CANTA) In A Good Position To Invest In Growth?
Nov 22An Intrinsic Calculation For Cantargia AB (publ) (STO:CANTA) Suggests It's 47% Undervalued
May 31Here's Why We're Not Too Worried About Cantargia's (STO:CANTA) Cash Burn Situation
May 02Is Cantargia (STO:CANTA) In A Good Position To Invest In Growth?
Jan 10We Think Cantargia (STO:CANTA) Can Easily Afford To Drive Business Growth
Sep 20Shareholder Returns
| CANTA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -0.9% | 0.6% | 0.3% |
| 1Y | -38.8% | -4.4% | 10.1% |
Return vs Industry: CANTA underperformed the Swedish Biotechs industry which returned -3.8% over the past year.
Return vs Market: CANTA underperformed the Swedish Market which returned 10.2% over the past year.
Price Volatility
| CANTA volatility | |
|---|---|
| CANTA Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 13.4% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: CANTA's share price has been volatile over the past 3 months.
Volatility Over Time: CANTA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 22 | Goran Forsberg | www.cantargia.com |
Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04 (Nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer and non-small cell lung cancer, as well as Phase Ib/II for the treatment of triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It is also developing CANxx, an IL1RAP-based antibody platform.
Cantargia AB (publ) Fundamentals Summary
| CANTA fundamental statistics | |
|---|---|
| Market cap | kr627.84m |
| Earnings (TTM) | -kr280.03m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.2x
P/E RatioIs CANTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CANTA income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr280.03m |
| Earnings | -kr280.03m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 21, 2024
| Earnings per share (EPS) | -1.52 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CANTA perform over the long term?
See historical performance and comparison